(RTTNews) - Celltrion USA, Inc., the U.S. subsidiary of Celltrion Inc. (068270.KS), will present two new analyses of ZYMFENTRA in patients with Crohn's disease and ulcerative colitis at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting on October 13 an
(RTTNews) - Oil prices traded higher on Monday, recouping early losses in the wake of fresh attacks on Saudi Arabia's aviation infrastructure by Iran-backed Houthi militants and a drone strike on a tanker near the Sohar anchorage off Oman.
(RTTNews) - European stocks traded higher on Monday, after having recovered from four-month lows in the previous session on U.S. President Trump's remarks dismissing speculation of pre-midterm military action against Iran.
(RTTNews) - Asian stocks turned in a mixed performance on Monday, with South Korean markets falling sharply due to worsening investor sentiment in the semiconductor sector on growing concerns over the AI industry in the U.S.
Key PointsFed Chair Warsh and 11 other voting members of the Federal Open Market Committee (FOMC) unanimously raised the federal funds target rate by 25 basis points to 3.75%-4.00% on Sept. 16.
(RTTNews) - Integra LifeSciences Holdings Corp. (IART), a global medical technology company, announced the pricing of $450 million aggregate principal amount of 9.5% senior secured notes due 2033.
(RTTNews) - First Tracks Biotherapeutics, Inc. (TRAX), a clinical-stage biotechnology company, is set to review top-line data from the Cohort 1 Phase 1b trial of ANB033 in celiac disease during an investor webcast on October 12, 2026.
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to opamtistomig (LBL-024), its investigational antibody, for the first-line treatment of advanced or metastatic biliary tract cancer
(RTTNews) - Foresee Pharmaceuticals (6576.TWO) said it was notified by licensing partner, Changchun GeneScience Pharmaceutical, that China's National Medical Products Administration has approved the Marketing Authorization Application for CAMCEVI 42 mg, a ready-to-use 6-month sub
(RTTNews) - Freenome, Inc. (FRNM), a company that develops blood tests for early cancer detection, announced it will present late-breaking data on an updated version of its SimpleScreen CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual M